Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
- ribonucleic acid
- Drug delivery
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 253926
Licensee shall have the sole rights, itself and/or through Affiliates or Sublicensees to Commercialize and otherwise exploit Licensed Products developed by Licensee for all uses in the Field of Use in the Territory.
Licensee has capabilities in the research and development of microRNA drug candidates and products and desires to obtain from Licensor, and Licensor is willing to grant to Licensee, a license under Licensors technology and intellectual property relating to Licensors liposomal delivery technology known as NOV340, to exclusively develop and commercialize drug products containing such delivery technology combined with one or more selected Licensee mircoRNA molecules worldwide.
IPSCIO Record ID: 255308
Licensor has capabilities in the research and development of microRNA drug candidates and products and desires to obtain from Licensee, and Licensee is willing to grant to Licensor, a license under Licensees technology and intellectual property relating to Licensees liposomal delivery technology known as NOV340, to exclusively develop and commercialize drug products containing such delivery technology combined with one or more selected Licensor mircoRNA molecules worldwide.
IPSCIO Record ID: 362429
Licensor grants to Licensee a revocable, limited, non-exclusive, non-transferable license in the United States and European Union member countries to use Licensorâ€™s Trademark â€œSMARTICLESÂ® liposomal delivery technologyâ€ and in all other countries in the Territory â€œSMARTICLESâ„¢ liposomal delivery technologyâ€ solely to research, develop, promote and sell Licensed Products. Notwithstanding the foregoing, any use or display of the Trademark by Licensee shall be in a manner that the Parties agree is commercially reasonable, which approval by Licensor shall not be unreasonably withheld. Licensor may, at its discretion, independently monitor Licenseeâ€™s use of the Trademark, and if Licensor perceives a use or display of its Trademark that is not in accordance with preciously approved submissions or is otherwise damaging to Licensor, Licensor may notify Licensee of such and Licensee shall correct such non-conformance or shall cease and desist such use or display within thirty (30) days of receipt of such notice.
Licensed Patent means
7,371,404 – Amphoteric liposomes are proposed, which comprise positive and negative membrane-based or membrane-forming charge carriers as well as the use of these liposomes.
7,780,983 – Amphoteric liposomes
7,858,117 – Amphoteric liposomes and their use
Licensee Compound means any DNAi oligonucleotide that is owned, controlled, developed or licensed by Licensee (or its Affiliate) for use in the Field of Use, such as NT200 through PNTl 000.
DNAi means all single stranded oligonucleotides that affect the non-transcribed region of a gene target. DNAi does not include RNAi, antisense and microRNA oligonucleotides that base pair with mRNAs, microRNAs or pre-mRNAs to affect expression of a gene, directly or indirectly.
PNT2258 is Licensee first DNAi oligonucleotide targeted against the anti-apoptotic bcl-2 oncogene and encapsulated in Marina's SMARTICLESÂ® technology. This novel delivery technology offers protection for the DNAi oligonucleotide during systemic administration with good circulation times and extrahepatic tumor exposure. DNAi are short single-strand unmodified oligonucleotides designed to silence genes by interfering with DNA. The DNAi silencing approach is differentiated from that of RNAi, antisense or miRNA in that it targets genomic sequences within the noncoding region of DNA disrupting transcription. The progress and delivery validation in the clinic this past year on the novel DNAi-SMARTICLESÂ® formulation gives us confidence to bring forward more first-in-class drug candidates alone or with partners.
IPSCIO Record ID: 263910
MicroRNAs have been shown to hold tremendous potential as a new class of prospective drug targets with significant therapeutic opportunity.
MicroRNAs (miRNAs) are a recently discovered, naturally occurring form of RNAi. These small RNAs act as protein regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNA expression levels have been shown to be correlated with various disease states and to hold great potential as diagnostics and prognostic markers
Licensee's lead therapeutic development program for liver cancer (hepatocellular carcinoma or HCC) has so far identified four microRNAs that when inhibited in vitro lead to a decrease in liver cancer cell proliferation.